Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.
Nowakowski GS, Willenbacher W, Greil R, Larsen TS, Patel K, Jäger U, Manges RF, Trümper L, Everaus H, Kalakonda N, Brown P, Jørgensen JM, Cunningham D, Dell'Aringa J, Fox B, Rubio ND, Kilavuz N, Casadebaig ML, Manzke O, Munoz J.
Nowakowski GS, et al. Among authors: manges rf.
Int J Hematol. 2022 Feb;115(2):222-232. doi: 10.1007/s12185-021-03241-4. Epub 2021 Nov 19.
Int J Hematol. 2022.
PMID: 34797531
Clinical Trial.